Bolstering its immuno-oncology pipeline, Sanofi (NASDAQ:SNY) will acquire all of the outstanding shares of Synthorx (NASDAQ:THOR) for $68 per share in cash, representing a 172% premium to the latter’s closing price on Dec. 6.
“This acquisition fits perfectly with our strategy
to build a portfolio of high-quality assets and to lead with
innovation, as you will hear at our Capital Markets Day tomorrow,” said
CEO Paul Hudson.
“Additionally, it is aligned with our goal to
build our oncology franchise with potentially practice-changing
medicines and novel combinations.”
https://seekingalpha.com/news/3524647-sanofi-to-buy-synthorx-for-2_5b
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.